Anticipating Resistance in HABP/VABP: Strategies to Improve Empiric Regimens in the ICU

In this live, in-person symposium, expert faculty will discuss empiric antimicrobial prescribing in HABP/VABP in the setting of antimicrobial resistance, including pneumonia caused by XDROs, using principles outlined in national guidelines, and other strategies such as use of advanced antibiograms and clinical pathways. The expert panel will address challenging case-based clinical scenarios focused on optimizing care in unique ICU settings and high-risk patients.

This is an affiliated event (not official IDWeek programming).



Strategies for Empiric Therapy in HABP/VABP

Key Aspects of Antimicrobial Resistance in HABP/VABP

Strategies for Effective Antimicrobial Resistance Risk Stratification

Question and Answer Session


Date / Time
Event Details


Marion Elligsen, BScPhm, RPh

Practice-Based Researcher
Sunnybrook Research Institute
Antimicrobial Stewardship Pharmacy Lead
Department of Pharmacy
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada

Keith S. Kaye, MD, MPH

Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Andrew Shorr, MD, MPH, MBA

Director, Pulmonary and Critical Care Medicine
Washington, DC

Goal Statement
The goal of this activity is to improve learners’ knowledge, competence, and performance in applying the latest practice guidance and data to provide appropriately broad empiric regimens for HABP/VABP in patients with risk factors for antimicrobial resistance.

Target Audience
This program is intended for physicians, pharmacists, and other healthcare professionals who care for patients with HABP and VABP.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Stratify patients with HABP/VABP who are at risk for XDROs based on local resistance patterns and patient-specific factors

  • Apply appropriate use of broad-spectrum antimicrobial agents for XDROs based on known or anticipated resistance mechanisms

  • Develop and integrate strategies for effective empiric coverage of patients with HABP/VABP who are at risk for XDROs


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category l Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.5 contact hours (.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-216-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.